ZymoGenetics, Inc. (NASDAQ:ZGEN), today announced the presentation of safety and immunogenicity data among pediatric burn patients at the 42nd Annual Meeting of the American Burn Association in Boston, MA. The study marks the first dedicated look at the safety and immunogenicity of any stand-alone thrombin in pediatric surgical patients. The investigators concluded that RECOTHROM did not appear to be associated with any treatment-related adverse events when used as an aid to hemostasis in pediatric patients undergoing synchronous burn wound excision and skin grafting… (Source: Health News from Medical News Today)

Further information:

Article source

Related posts:

1. Cytokinetics Announces Non-Clinical Data From Multiple Programs to Be Presented at the Biophysical Society 54th Annual Meeting
2. Has The Advent Of Minimally Invasive Surgery Altered The Risk Profile Of Patients Undergoing Prostatectomy?
3. COPPERTONE(R) Solar Research Center Unveils Studies On Efficacy Of Topical Antioxidants In Sunscreens At 2010 Annual Meeting
4. Burn injuries due to Christian religious customs
5. CRP Found to Have Implication for Patients After Undergoing Surgery